STAT3 and neoplasm: JSI-124 PLGA NPs have great anti-tumor activity against B16 melanoma cells by reducing the expression of STAT3 in DCs and enhancing the function of DCs in terms of promoting the production of T cells leading to the cancer immunotherapy [205].